-+ 0.00%
-+ 0.00%
-+ 0.00%

Oppenheimer Maintains Outperform on Larimar Therapeutics, Lowers Price Target to $21

Benzinga·10/02/2025 13:27:47
Listen to the news
Oppenheimer analyst Andreas Argyrides maintains Larimar Therapeutics (NASDAQ:LRMR) with a Outperform and lowers the price target from $26 to $21.